Five clinical trials of DC-based immunotherapy demonstrated that MGMT methylation was an indicator of favorable prognosis in GBM patients [4, 20–24]; however, two trials presented contrasting results [25, 26]. The gene discussed is MGMT; the disease is glioblastoma.